The inhibition of pro-inflammatory cytokines with pentoxifylline in the cardiopulmunary bypass lung
dc.contributor.author | Bakır, Kemal | |
dc.contributor.author | Sivrikoz, Muammer Cumhur | |
dc.contributor.author | Erbağcı, Burak | |
dc.contributor.author | Uçak, Ramazan | |
dc.contributor.author | Nurozler, Feza | |
dc.contributor.author | Üstünsoy, Haşim | |
dc.contributor.buuauthor | Şenkaya, Işık | |
dc.contributor.department | Uludağ Üniversitesi/Tıp Fakültesi/Kardiyovasküler Cerrahi Anabilim Dalı. | tr_TR |
dc.contributor.scopusid | 15827259500 | tr_TR |
dc.date.accessioned | 2021-11-30T13:09:25Z | |
dc.date.available | 2021-11-30T13:09:25Z | |
dc.date.issued | 2002-04 | |
dc.description.abstract | In addition to preventing tissue energy loss during cardiopulmonary bypass. pentoxifylline (Ptx) prevents the production of pro-inflammatory cytokines as well. The aim of this study was to investigate whether Ptx decreases the inflammatory effects of cardiopulmonary bypass on the lungs during open-heart surgery, The patients in the study group (n=15) who were going through an open-heart surgery had 500 mg l(-1) of Ptx added to their prime solution, whereas the patients in the control group (n=10) only received prime solution. Pre-pump and post-pump blood samples were obtained from both groups and assayed for intereukin-6 (IL-6), interleukin-8 (IL-8) and tumour necrosis factor alpha (TNFalpha), Lung tissue samples that were obtained after the pump were examined with light microscopy and stained for tissue TNFalpha Non-parametric Wilcoxon test was utilized for statistical evaluation, In the post-pump period, the difference in the IL-6, IL-8 and TNFalpha levels of the two groups was found to be statistically significant (P < 0.005). The tissue samples from the control group had significant staining with TNFalpha. We think that Ptx has important protective effects on the lungs during cardiopulmonary bypass. | tr_TR |
dc.identifier.citation | Üstünsoy H. vd. (2002). "The inhibition of pro-inflammatory cytokines with pentoxifylline in the cardiopulmunary bypass lung". Respiratory Medicine, 96(4), 275-279. | tr_TR |
dc.identifier.endpage | 279 | tr_TR |
dc.identifier.issn | 0954-6111 | |
dc.identifier.issue | 4 | tr_TR |
dc.identifier.pubmed | 12000008 | tr_TR |
dc.identifier.scopus | 2-s2.0-0036553573 | tr_TR |
dc.identifier.startpage | 275 | tr_TR |
dc.identifier.uri | https://doi.org/10.1053/rmed.2001.1255 | |
dc.identifier.uri | https://www.sciencedirect.com/science/article/pii/S0954611101912557 | |
dc.identifier.uri | http://hdl.handle.net/11452/22893 | |
dc.identifier.volume | 96 | tr_TR |
dc.identifier.wos | 000175123200011 | tr_TR |
dc.indexed.pubmed | Pubmed | tr_TR |
dc.indexed.scopus | Scopus | tr_TR |
dc.indexed.wos | SCIE | tr_TR |
dc.language.iso | en | tr_TR |
dc.publisher | W B Saunders | tr_TR |
dc.relation.collaboration | Yurtiçi | tr_TR |
dc.relation.journal | Respiratory Medicine | tr_TR |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi | tr_TR |
dc.rights | info:eu-repo/semantics/openAccess | tr_TR |
dc.subject | Pentoxifylline | tr_TR |
dc.subject | Lung | tr_TR |
dc.subject | Inflammatory response | tr_TR |
dc.subject | Cardiopulmonary bypass | tr_TR |
dc.subject | Myocardial protection | tr_TR |
dc.subject | Ischemia | tr_TR |
dc.subject | Reperfusion | tr_TR |
dc.subject | Injury | tr_TR |
dc.subject | Cardiovascular system & cardiology | tr_TR |
dc.subject | Respiratory system | tr_TR |
dc.subject.emtree | Adult | tr_TR |
dc.subject.emtree | Antiinflammatory activity | tr_TR |
dc.subject.emtree | Article | tr_TR |
dc.subject.emtree | Blood pump | tr_TR |
dc.subject.emtree | Blood sampling | tr_TR |
dc.subject.emtree | Cardiopulmonary bypass | tr_TR |
dc.subject.emtree | Chemoluminescence | tr_TR |
dc.subject.emtree | Clinical article | tr_TR |
dc.subject.emtree | Female | tr_TR |
dc.subject.emtree | Clinical trial | tr_TR |
dc.subject.emtree | Controlled clinical trial | tr_TR |
dc.subject.emtree | Controlled study | tr_TR |
dc.subject.emtree | Drug mechanism | tr_TR |
dc.subject.emtree | Human | tr_TR |
dc.subject.emtree | Heart ventricle septum defect | tr_TR |
dc.subject.emtree | Histology | tr_TR |
dc.subject.emtree | Human tissue | tr_TR |
dc.subject.emtree | Immunoassay | tr_TR |
dc.subject.emtree | Male | tr_TR |
dc.subject.emtree | Lung biopsy | tr_TR |
dc.subject.emtree | Open heart surgery | tr_TR |
dc.subject.emtree | Pneumonia | tr_TR |
dc.subject.emtree | Priority journal | tr_TR |
dc.subject.emtree | Rank sum test | tr_TR |
dc.subject.emtree | Statistical significance | tr_TR |
dc.subject.emtree | Valvular heart disease | tr_TR |
dc.subject.emtree | Antibiotic agent | tr_TR |
dc.subject.emtree | Bicarbonate | tr_TR |
dc.subject.emtree | Corticosteroid | tr_TR |
dc.subject.emtree | Cytokine | tr_TR |
dc.subject.emtree | İnterleukin 6 | tr_TR |
dc.subject.emtree | Interleukin 8 | tr_TR |
dc.subject.emtree | Mannitol | tr_TR |
dc.subject.emtree | Pentoxifylline | tr_TR |
dc.subject.emtree | Ringer lactate solution | tr_TR |
dc.subject.emtree | Tumor necrosis factor alpha | tr_TR |
dc.subject.scopus | Pentoxifylline; Methylxanthine; Phosphodiesterase Inhibitors | tr_TR |
dc.subject.wos | Cardiac & cardiovascular systems | tr_TR |
dc.subject.wos | Respiratory system | tr_TR |
dc.title | The inhibition of pro-inflammatory cytokines with pentoxifylline in the cardiopulmunary bypass lung | tr_TR |
dc.type | Article | |
dc.wos.quartile | Q2 (Cardiac & cardiovascular systems) | tr_TR |
dc.wos.quartile | Q3 (Respiratory system) | tr_TR |